Table 3.

Initial data set and validation set results according to axillary nodal macro metastasis involvement

	Initial set					Validation set
	pN0 pN1mi		macro			pN0pN1mi		macro
	Nb	%	Nb	%	p	Nb	%	Nb	%	p
Nb patients	6400		1981			3178		1013
Age median (range)	58.4 (18–101)		55 (20–98)			59 (18–100)		56 (25–90)
<  60	3573	56	128/4	65	< 0.0001	1743	55	631	62	0.0002
61–65	934	15	232	12		510	16	134	13
>  65	1891	30	464	23		922	29	248	24
Tumor size
< 10	2872	45	264	13	< 0.0001	1453	46	112	11	< 0.0001
11 to 20	2665	42	703	36		1310	42	375	37
> 20	786	12	998	51		380	12	515	51
Tumor type
Ductal	4981	78	1541	78	< 0.0001	2494	79	777	77	< 0.0001
Lobular	800	13	310	16		382	12	153	15
Mixt	82	1	62	3		43	1	39	4
Others	531	8	68	3		257	8	43	4
Grade
1	2442	39	449	23	< 0.0001	1147	37	208	21	< 0.0001
2	2841	45	959	49		1453	46	503	50
3	1048	17	563	29		540	17	297	29
LVI
Negative	4655	86	1006	55	< 0.0001	2287	86	482	53	< 0.0001
Positive	780	14	815	45		373	14	432	47
Estrogen receptors
negative	827	13	319	16	0.0003	414	13	170	17	0.0031
positive	5570	87	1657	84		2760	87	841	83
Progesterone receptors
negative	1751	29	530	28	0.4585	885	29	298	30	0.6346
positive	4330	71	1371	72		2140	71	681	70
Hormonal receptors
negative	732	11	288	15	0.0002	375	12	146	14	0.0306
positive	5662	89	1687	85		2800	88	864	86
Tumor sub types
Luminal A	4780	75	1246	63	< 0.0001	2345	74	627	62	< 0.0001
Luminal B Her2-	458	7	298	15		272	9	150	15
HR+ Her2+	383	6	138	7		161	5	84	8
HR- Her 2+	178	3	110	6		106	3	56	6
Triple Negative	554	9	178	9		269	9	90	9
Clinical size
T0	1601	26	230	12	< 0.0001	828	27	105	11	< 0.0001
T1	3731	61	813	43		1835	61	405	42
T2	710	12	673	36		348	11	384	40
> T3	30	0	157	8		20	1	76	8